LGR5 and head and neck squamous cell carcinoma: The therapeutic approach of using LGR5 even as a biological target [38] was recently very successful in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) as a phase 2 study (NCT03526835) [59].